§ Federal grant opportunity · RFA-TR-25-016
Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed)
National Institutes of Health is accepting applications for Intramural - Extramural Collaboration for Advanced 3-D Tissue Models for Drug Screening (Clinical Trial Not Allowed). The deadline is Rolling / not published and the published award range is Award amount not published.
Key facts
- Funder
- National Institutes of Health
- Application deadline
- Rolling / not published
- Award range
- Award amount not published
- Eligibility
- city or township governments, county governments, nonprofits non higher education with 501c3, state governments, special district governments, small businesses, independent school districts, nonprofits non higher education without 501c3, private institutions of higher education, other, other native american tribal organizations, for profit organizations other than small businesses, public and state institutions of higher education, public and indian housing authorities, federally recognized native american tribal governments
- Geography
- United States
- Focus areas
- Health
- Opportunity number
- RFA-TR-25-016
Program overview
NIH intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that will develop, validate and demonstrate the utility of advanced 3-D tissue models for testing the efficacy of various therapeutic modalities, including small molecules and biologics and accelerate the discovery and development of new therapeutics across different diseases. The initiative will develop advanced 3-D drug screening models adaptable to high throughput assays. These non-animal models are expected to mimic structural, biochemical and mechanical properties of tissue that are representative of a drug’s behavior in a body, resulting in improved predictive accuracy. This is an expansion upon the work conducted under previous NOFOs, RFA-TR-17-007, RFA-TR-19-020 and RFA-TR-21-015, that have focused on development of 3-D skin and other tissue models for drug screening. The applicants are required to utilize the 3-D modeling/drug screening expertise and infrastructure available at the NCATS 3-D Bioprinting laboratory. 3-D tissue models in a well-based drug screening platform should be as complex as necessary to achieve physiological/pharmacological relevance, and as simple as possible to make the models robust, reliable and amenable to drug screening. Grant authorities that allow NCATS to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from National Institutes of Health.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before Rolling / not published, allowing time for registration and validation.
Related grant opportunities
- Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
- NEI New Innovator Award (DP2 Clinical Trial Not Allowed)
- The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genomic Research Centers
- HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
- NIJ FY 2026 Research on Gender Dysphoria and Violent Crime
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.